Shared risk factors in cardiovascular disease and cancer

Circulation

Volumn 133, Issue 11, 2016, Pages 1104-1114

  Koene, Ryan J ^a   Prizment, Anna E ^b,c   Blaes, Anne ^b   Konety, Suma H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cardiology; Cardiovascular diseases; Clinical oncology; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; META ANALYSIS (TOPIC); NEOPLASM; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; ADULT; ADVERSE EFFECTS; AGE; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DRINKING BEHAVIOR; FEMALE; HYPERINSULINISM; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEOPLASMS; UNITED STATES;

ADULT; AGE FACTORS; AGED; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DIET; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERINSULINISM; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEOPLASMS; OBESITY; OXIDATIVE STRESS; RISK FACTORS; SMOKING; UNITED STATES;

EID: 84961773397     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.020406     Document Type: Article

References (113)

1. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61:1-51.
2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944. doi: 10.1161/CIR.0b013e31820a55f5.
4. Coussens LM, Werb Z. Infammation and cancer. Nature. 2002;420:860-867. doi: 10.1038/nature01322.
5. Libby P. Infammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S-460S.
6. Berg AH, Scherer PE. Adipose tissue, infammation, and cardiovascular disease. Circ Res. 2005;96:939-949. doi: 10.1161/01. RES.0000163635.62927.34.
7. Frayn K, Bernard S, Spalding K, Arner P. Adipocyte triglyceride turnover is independently associated with atherogenic dyslipidemia. J Am Heart Assoc. 2012;1:e003467. doi: 10.1161/JAHA.112.003467.
8. Rodríguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ. The immunological basis of hypertension. Am J Hypertens. 2014;27:1327-1337. doi: 10.1093/ajh/hpu142.
9. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Infammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072.
10. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting infammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425-430. doi: 10.1158/1078-0432. CCR-08-0149.
11. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol. 1992;263(2 pt 2):H321-H326.
12. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000;45:391-418.
13. Kamp DW, Shacter E, Weitzman SA. Chronic infammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25:400-410, 413.
14. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094-1098. doi: 10.1126/science.1241908.
15. Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012;2012:137289. doi: 10.5402/2012/137289.
16. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S, Yongvanit P, Kawanishi S, Murata M. Oxidative stress and its signifcant roles in neu-rodegenerative diseases and cancer. Int J Mol Sci. 2015;16:193-217. doi: 10.3390/ijms16010193.
17. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45.
18. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD; American Heart Association Strategic Planning Task Force and Statistics Committee. Defning and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586-613. doi: 10.1161/CIRCULATIONAHA.109.192703.
19. Barreira TV, Harrington DM, Katzmarzyk PT. Cardiovascular health metrics and accelerometer-measured physical activity levels: National Health and Nutrition Examination Survey, 2003-2006. Mayo Clin Proc. 2014;89:81-86. doi: 10.1016/j.mayocp.2013.10.001.
20. Laitinen TT, Pahkala K, Magnussen CG, Viikari JS, Oikonen M, Taittonen L, Mikkilä V, Jokinen E, Hutri-Kähönen N, Laitinen T, Kähönen M, Lehtimäki T, Raitakari OT, Juonala M. Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation. 2012;125:1971-1978. doi: 10.1161/CIRCULATIONAHA.111.073585.
21. Rasmussen-Torvik LJ, Shay CM, Abramson JG, Friedrich CA, Nettleton JA, Prizment AE, Folsom AR. Ideal cardiovascular health is inversely associated with incident cancer: the Atherosclerosis Risk In Communities study. Circulation. 2013;127:1270-1275. doi: 10.1161/CIRCULATIONAHA.112.001183.
22. Cancer. Geneva, Switzerland: World Health Organization. http://www. who.int/mediacentre/factsheets/fs297/en/). Accessed December 27, 2015.
23. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-2698.
24. Litwin SE. Cardiac remodeling in obesity: time for a new paradigm. JACC Cardiovasc Imaging. 2010;3:275-277. doi: 10.1016/j.jcmg.2009.12.004.
25. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15:556-565. doi: 10.1634/theoncologist.2009-0285.
26. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. doi: 10.1016/S0140-6736(08)60269-X.
27. Dobbins M, Decorby K, Choi BC. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med. 2013;2013:680536. doi: 10.5402/2013/680536.
28. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.
29. Stocks T, Van Hemelrijck M, Manjer J, Bjørge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012;59:802-810. doi: 10.1161/HYPERTENSIONAHA.111.189258.
30. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, Boyle P. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122:155-164. doi: 10.1002/ijc.23033.
31. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66:1054-1064. doi: 10.1016/j.eururo.2014.08.059.
32. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T. Dietary fbre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011;343:d6617.
33. Magalhães B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2012;21:15-23. doi: 10.1097/CEJ.0b013e3283472241.
34. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic review and meta-analysis of physical activity and endo-metrial cancer risk. Eur J Epidemiol. 2015;30:397-412. doi: 10.1007/s10654-015-0017-6.
35. Robsahm TE, Aagnes B, Hjartåker A, Langseth H, Bray FI, Larsen IK. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. Eur J Cancer Prev. 2013;22:492-505. doi: 10.1097/CEJ.0b013e328360f434.
36. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2013;137:869-882. doi: 10.1007/s10549-012-2396-7.
37. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee I-M, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-2219.
38. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjønneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Guernec G, Bergmann MM, Linseisen J, Becker N, Trichopoulou A, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Van Guelpen B, Palmqvist R, Berglund G, Gonzalez CA, Dorronsoro M, Barricarte A, Navarro C, Martinez C, Quirós JR, Roddam A, Allen N, Bingham S, Khaw KT, Ferrari P, Kaaks R, Slimani N, Riboli E. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920-931. doi: 10.1093/jnci/djj246.
39. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 2015;5:19. doi: 10.3389/fonc.2015.00019.
40. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312. doi: 10.1038/35053000.
41. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer. 2010;10:442. doi: 10.1186/1471-2407-10-442.
42. Hou N, Luo JD. Leptin and cardiovascular diseases. Clin Exp Pharmacol Physiol. 2011;38:905-913. doi: 10.1111/j.1440-1681.2011.05619.x.
43. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-910. doi: 10.1016/j.ctrv.2012.04.007.
44. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685. doi: 10.2337/dc10-0666.
45. Satija A, Spiegelman D, Giovannucci E, Hu FB. Type 2 diabetes and risk of cancer. BMJ. 2015;350:g7707.
46. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346-1353. doi: 10.1016/S0140-6736(04)16044-3.
47. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet. 2009;17:1668-1675. doi: 10.1038/ejhg.2009.86.
48. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531-1543.
49. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109:687-696. doi: 10.1161/CIRCRESAHA.110.236687.
50. Shoelson SE, Lee J, Goldfne AB. Infammation and insulin resistance. J Clin Invest. 2006;116:1793-1801. doi: 10.1172/JCI29069.
51. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial infammatory response: a new perspective. Hypertension. 1995;25:155-161.
52. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327-334. doi: 10.1161/CIRCULATIONAHA.108.845792.
53. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112:479-486.
54. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip G Y. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens. 2003;16:11-20.
55. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803. doi: 10.1038/nrc909.
56. Kang YS, Park YG, Kim BK, Han SY, Jee YH, Han KH, Lee MH, Song HK, Cha DR, Kang SW, Han DS. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol. 2006;36:377-388. doi: 10.1677/jme.1.02033.
57. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
58. Alexopoulos CG, Blatsios B, Avgerinos A. Serum lipids and lipoprotein disorders in cancer patients. Cancer. 1987;60:3065-3070.
59. Gabitova L, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res. 2014;20:28-34. doi: 10.1158/1078-0432.CCR-13-0122.
60. Tseng TH, Hsu JD, Chu CY, Wang CJ. Promotion of colon carcinogenesis through increasing lipid peroxidation induced in rats by a high cholesterol diet. Cancer Lett. 1996;100:81-87.
61. Reddy BS. Diet and excretion of bile acids. Cancer Res. 1981;41(9 Pt 2):3766-3768.
62. Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014;370:572-573. doi: 10.1056/NEJMcibr1315176.
63. Morris PB, Ference BA, Jahangir E, Feldman DN, Ryan JJ, Bahrami H, El-Chami MF, Bhakta S, Winchester DE, Al-Mallah MH, Sanchez Shields M, Deedwania P, Mehta LS, Phan BA, Benowitz NL. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol. 2015;66:1378-1391. doi: 10.1016/j. jacc.2015.07.037.
64. Leikauf GD, Borchers MT, Prows DR, Simpson LG. Mucin apoprotein expression in COPD. Chest. 2002;121(5 suppl):166S-182S.
65. Dietary patterns, foods and nutrients, and health outcomes, Part D, Chapter 2. Scientifc Report of the 2015 Dietary Guidelines Advisory Committee. http://health.gov/dietaryguidelines/2015-scientifc-report/PDFs/07-Part-D-Chapter-2.pdf Accessed October 10, 2015.
66. Stampfer M, Jahn JL. Partnerships for promoting prevention. Circulation. 2013;127:1267-1269. doi: 10.1161/CIRCULATIONAHA.113.001288.
67. Wang T, Lee HG. Advances in research on cis-9, trans-11 conjugated lin-oleic acid: a major functional conjugated linoleic acid isomer. Crit Rev Food Sci Nutr. 2015;55:720-731. doi: 10.1080/10408398.2012.674071.
68. English DR, MacInnis RJ, Hodge AM, Hopper JL, Haydon AM, Giles GG. Red meat, chicken, and fsh consumption and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1509-1514.
69. Wood AD, Strachan AA, Thies F, Aucott LS, Reid DM, Hardcastle AC, Mavroeidi A, Simpson WG, Duthie GG, Macdonald HM. Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic infammation and cardiovascular risk. Br J Nutr. 2014;112:1341-1352. doi: 10.1017/S0007114514001962.
70. Baena Ruiz R, Salinas Hernández P. Diet and cancer: risk factors and epidemiological evidence. Maturitas. 2014;77:202-208. doi: 10.1016/j. maturitas.2013.11.010.
71. Chang YJ, Myung SK, Chung ST, Kim Y, Lee EH, Jeon YJ, Park CH, Seo HG, Huh BY. Effects of vitamin treatment or supplements with purported antioxidant properties on skin cancer prevention: a meta-analysis of randomized controlled trials. Dermatology. 2011;223:36-44. doi: 10.1159/000329439.
72. MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, Suttorp MJ, Lim YW, Traina SB, Hilton L, Garland R, Morton SC. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA. 2006;295:403-415. doi: 10.1001/jama.295.4.403.
73. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.
74. Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetano G. Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease. Circulation. 2010;121:1951-1959. doi: 10.1161/CIRCULATIONAHA.109.865840.
75. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107:443-447.
76. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks Hum. 2010;96:3-1383.
77. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, Pelucchi C, Bellocco R, Negri E, Corrao G, Rehm J, Boffetta P, La Vecchia C. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol. 2013;24:301-308. doi: 10.1093/annonc/mds337.
78. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7:149-156. doi: 10.1016/S1470-2045(06)70577-0.
79. Myers J. Exercise and cardiovascular health. Circulation. 2003;107:2e-5.
80. Li T, Wei S, Shi Y, Pang S, Qin Q, Yin J, Deng Y, Chen Q, Wei S, Nie S, Liu L. The dose-response effect of physical activity on cancer mortality: fndings from 71 prospective cohort studies (published online ahead of print September 18, 2015). Br J Sports Med. doi: 10.1136/bjsports-2015-094927. http://bjsm.bmj.com/content/early/2015/09/18/bjsports-2015-094927. long. Accessed December 27, 2015.
81. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132(11 suppl):3456S-3464S.
82. Sur I, Tuupanen S, Whitington T, Aaltonen LA, Taipale J. Lessons from functional analysis of genome-wide association studies. Cancer Res. 2013;73:4180-4184. doi: 10.1158/0008-5472.CAN-13-0789.
83. Henley SJ, Singh S, King J, Wilson R, Ryerson B; Centers for Disease Control and Prevention (CDC). Invasive cancer incidence-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63:253-259.
84. Frieden TR; Centers for Disease Control and Prevention (CDC). CDC health disparities and inequalities report-United States, 2013. Foreword. MMWR Surveill Summ. 2013;62(suppl 3):1-2.
85. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG; Diabetes and Cancer Research Consortium. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55:1607-1618. doi: 10.1007/s00125-012-2525-1.
86. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143-156. doi: 10.1038/nrendo.2013.256.
87. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A, Marchionni N, Rotella CM. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010;33:1997-2003. doi: 10.2337/dc10-0476.
88. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-1744. doi: 10.1007/s00125-009-1418-4.
89. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol. 1999;83:1090-1093.
90. Lijinsky W, Reuber MD. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health. 1987;3:413-422.
91. National Toxicology P. Toxicology and carcinogenesis studies of furose-mide (CAS No. 54-31-9) in F344/N rats and B6C3F1 mice (feed studies). Natl Toxicol Program Tech Rep Ser. 1989;356:1-190.
92. Chow WH, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Risk of renal cell cancer in relation to diuretics, antihyperten-sive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev. 1995;4:327-331.
93. McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, McCredie M, Lindblad P, Schlehofer B, Pommer W, Niwa S, Adami HO. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer. 1995;63:216-221.
94. Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control. 1993;4:555-558.
95. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the infuence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129:549-556. doi: 10.1007/s10549-011-1505-3.
96. Warita K, Warita T, Beckwitt CH, Schurdak ME, Vazquez A, Wells A, Oltvai ZN. Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep. 2014;4:7593. doi: 10.1038/srep07593.
97. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80. doi: 10.1001/jama.295.1.74.
98. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792-1802. doi: 10.1056/NEJMoa1201735.
99. Mucci LA, Stampfer MJ. Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer. J Clin Oncol. 2014;32:1-2. doi: 10.1200/JCO.2013.53.2770.
100. Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat Rev. 2015;41:554-567. doi: 10.1016/j. ctrv.2015.04.005.
101. Shebl FM, Hsing AW, Park Y, Hollenbeck AR, Chu LW, Meyer TE, Koshiol J. Non-steroidal anti-infammatory drugs use is associated with reduced risk of infammation-associated cancers: NIH-AARP study. PLoS One. 2014;9:e114633. doi: 10.1371/journal.pone.0114633.
102. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of fve randomised trials. Lancet. 2010;376:1741-1750. doi: 10.1016/S0140-6736(10)61543-7.
103. Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol. 2011;25:461-472. doi: 10.1016/j. bpg.2011.10.015.
104. Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10:697-710. doi: 10.1038/nrclinonc.2013.195.
105. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20:816-827. doi: 10.1093/annonc/mdn728.
106. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311-319. doi: 10.1002/cncr.28972.
107. Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol. 2010;28:3407-3410. doi: 10.1200/JCO.2009.26.0125.
108. Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol. 2006;24:4056-4058. doi: 10.1200/JCO.2006.07.5143.
109. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3:e000472. doi: 10.1161/JAHA.113.000472.
110. Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, Sklar CA, Robison LL, Oeffnger KC. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32:1218-1227. doi: 10.1200/JCO.2013.51.1055.
111. Armstrong GT, Oeffnger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR. Modifable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673-3680. doi: 10.1200/JCO.2013.49.3205.
112. Nöthlings U, Ford ES, Kröger J, Boeing H. Lifestyle factors and mortality among adults with diabetes: fndings from the European Prospective Investigation into Cancer and Nutrition-Potsdam study∗. J Diabetes. 2010;2:112-117. doi: 10.1111/j.1753-0407.2010.00069.x.
113. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004;45(suppl 2):S3-S9. doi: 10.1016/j.lungcan.2004.07.998.